Wednesday, February 10, 2010, 7:52pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Human Genome Sciences Inc. (HGSI)

At 5:00AM SGT: 27.06 USD   0.00 (0.00%)  
 MORE ON HGSI 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Human Genome Sciences, Inc. (NGM:HGSI) Delayed quote dataEdit
Last Trade:27.06 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:27.06
Open:N/A
Bid:24.91 x 200
Ask:27.99 x 100
1y Target Est:34.07
Day's Range:N/A - N/A
52wk Range:0.45 - 32.07
Volume:0
Avg Vol (3m):4,153,480
Market Cap:4.47B
P/E (ttm):N/A
EPS (ttm):-0.16
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add HGSI to Portfolio   Download Data

 HEADLINES 
•UK court overturns GSK patent for lupus drug
at FT.com (Wed 7:10am)
•UK court rules HGS gene patent invalid -lawyers
at Reuters (Wed 12:39am)
•Biotech ETFs Immune To Broad Selling
Investor's Business Daily (Tue 6:34am)
•[$$] Biotech ETFs Are Looking Healthy
at RealMoney by TheStreet.com (Tue 5:50am)
•Friday Options Recap: Defensive Trading
at Seeking Alpha (Sat, Feb 6)
•Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO Investor Conference
Business Wire (Fri, Feb 5)
•Glaxo Brings Home the Bacon
at Motley Fool (Fri, Feb 5)
•The Answer You've Been Waiting For
at Motley Fool (Wed, Feb 3)
•3 Best Hedge Fund Healthcare Ideas
at Seeking Alpha (Wed, Feb 3)
•Human Genome Sciences Names Scott Habig Vice President, Sales
Business Wire (Mon, Feb 1)
•Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result?
Wall Street Transcript (Thu, Jan 28)
•Coverage initiated on Human Genome by RBC Capital Mkts
Briefing.com (Wed, Jan 27)
More Headlines for HGSI...
 ANALYST 
EPS Est (next year) (Dec-09) :0.05
EPS Est (in 2 years) (Dec-10) :-0.72
Avg Rec (current)*:1.7
PEG Ratio:120.60
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices